000307662 001__ 307662
000307662 005__ 20260224142407.0
000307662 0247_ $$2doi$$a10.1093/neuonc/noag006
000307662 0247_ $$2pmid$$apmid:41537229
000307662 0247_ $$2ISSN$$a1522-8517
000307662 0247_ $$2ISSN$$a1523-5866
000307662 037__ $$aDKFZ-2026-00119
000307662 041__ $$aEnglish
000307662 082__ $$a610
000307662 1001_ $$0P:(DE-He78)a0f4be29220ff87fa75aac74ac0bc49a$$aKoch, Marilin$$b0$$eFirst author$$udkfz
000307662 245__ $$aKMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis.
000307662 260__ $$aOxford$$bOxford Univ. Press$$c2026
000307662 3367_ $$2DRIVER$$aarticle
000307662 3367_ $$2DataCite$$aOutput Types/Journal article
000307662 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1768917053_2403417
000307662 3367_ $$2BibTeX$$aARTICLE
000307662 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307662 3367_ $$00$$2EndNote$$aJournal Article
000307662 500__ $$a#EA:B320#LA:B320#? / #DKTKZFB26# / #NCTZFB26# / epub
000307662 520__ $$aIDH1R132H is the defining mutation of low-grade gliomas (LGGs), inflicting broad epigenetic rewiring that leads to malignant transformation. Recent studies demonstrated that cell fate change from astrocyte to LGG is accompanied by redistribution of H3K4 methylation. By modulating H3K4-methyltransferase KMT2A in a conditionally IDH1R132H-expressing human astrocyte model system, we sought to define requirements of IDH1R132H dependent gliomagenesis and identify novel therapeutic targets.Using KMT2A inhibitor MM-102, we targeted H3K4me3 in IDH1R132H -expressing astrocytes, profiling L1CAM expression, proliferation, clonogenicity, invasion and migration, transcriptional and translational changes. Findings were validated in patient-derived IDH1R132H glioma lines with shRNA-mediated knockdown. Epigenetic transformation was characterized with CUT&Tag and MethylationEPIC. Downstream targets were assessed utilizing siRNAs.KMT2A inhibition significantly decreased L1CAM expression and led to broad transcriptional downregulation, including LGG marker genes. Analyses of transcriptomics and proteomics pointed to altered lipid metabolism and migratory capacity. Phenotypic characterization showed impaired invasion, migration and proliferation. We observed significantly reduced deposition of H3K4me3 at promoters of DEGs and enhanced global DNA methylation. We identified SCD as putative KMT2A-dependent effector whose knockdown reduced clonogenicity. In patient-derived models, KMT2A suppression impaired viability and spheroid growth in vitro; however, in an orthotopic TS603 model, knockdown shortened survival, indicating stage- and context-dependent effects.Disrupting KMT2A-mediated H3K4me3 reshapes the epigenome and attenuates LGG-relevant programs and phenotypes in vitro, supporting a strong role in tumor initiation. In vivo, the TS603 survival result highlights context-dependent maintenance and motivates cautious, microenvironment-aware therapeutic exploration of the KMT2A axis and downstream targets such as SCD.
000307662 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000307662 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307662 650_7 $$2Other$$aH3K4me3
000307662 650_7 $$2Other$$aKMT2A
000307662 650_7 $$2Other$$aepigenetics
000307662 650_7 $$2Other$$agliomagenesis
000307662 650_7 $$2Other$$alow-grade glioma
000307662 7001_ $$0P:(DE-He78)f1362f27ff6ee28959d9162dcba2e71e$$aDeo, Minh$$b1$$udkfz
000307662 7001_ $$0P:(DE-He78)2a599a43bd0b5910c80edb288d8da3e5$$aSchmidt, Claudia$$b2$$udkfz
000307662 7001_ $$0P:(DE-He78)790cf58133fee568cd2bf4355853543c$$aPodolak, Adrianna$$b3$$udkfz
000307662 7001_ $$0P:(DE-He78)b7bbfa7c998d298484f881999928daa4$$aTaranda, Julian$$b4$$udkfz
000307662 7001_ $$aHoetker, Michael S$$b5
000307662 7001_ $$0P:(DE-HGF)0$$aTurcan, Sevin$$b6
000307662 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noag006$$gp. noag006$$pnn$$tNeuro-Oncology$$vnn$$x1522-8517$$y2026
000307662 8564_ $$uhttps://inrepo02.dkfz.de/record/307662/files/noag006-1.pdf
000307662 8564_ $$uhttps://inrepo02.dkfz.de/record/307662/files/noag006-1.pdf?subformat=pdfa$$xpdfa
000307662 909CO $$ooai:inrepo02.dkfz.de:307662$$pVDB
000307662 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0f4be29220ff87fa75aac74ac0bc49a$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000307662 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f1362f27ff6ee28959d9162dcba2e71e$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000307662 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2a599a43bd0b5910c80edb288d8da3e5$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000307662 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)790cf58133fee568cd2bf4355853543c$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000307662 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b7bbfa7c998d298484f881999928daa4$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000307662 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000307662 9141_ $$y2026
000307662 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
000307662 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
000307662 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000307662 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000307662 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000307662 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000307662 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000307662 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000307662 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000307662 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
000307662 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000307662 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000307662 9201_ $$0I:(DE-He78)W250-20160331$$kW250$$lPräklinische und Translationale Pathologie Core Facility$$x2
000307662 9201_ $$0I:(DE-He78)HD02-20160331$$kHD02$$lKoordinierungsstelle NCT Heidelberg$$x3
000307662 9200_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000307662 980__ $$ajournal
000307662 980__ $$aVDB
000307662 980__ $$aI:(DE-He78)B320-20160331
000307662 980__ $$aI:(DE-He78)HD01-20160331
000307662 980__ $$aI:(DE-He78)W250-20160331
000307662 980__ $$aI:(DE-He78)HD02-20160331
000307662 980__ $$aUNRESTRICTED